Information:
Fel:
ID
44055
Beskrivning
Study documentation part: Pre-Treatment This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3.
Nyckelord
Versioner (4)
- 2015-07-06 2015-07-06 -
- 2015-08-06 2015-08-06 -
- 2021-03-15 2021-03-15 - Dr. rer. medic Philipp Neuhaus
- 2021-09-20 2021-09-20 -
Uppladdad den
20 september 2021
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0 Legacy
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Pre-Treatment
Pre- treatment status
Similar models
Pre- treatment status
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
PRE-TREATMENT STATUS
Item
Will the subject enter the treatment phase of this study?
boolean
Item Group
PRIMARY REASON FOR NOT ENTERING THE TREATMENT PHASE OF THIS STUDY (Fill only if study entry is denied)
ADVERSE EVENT
Item
Adverse event:
boolean
C0877248 (UMLS CUI-1)
CONSENT
Item
Subject withdrew consent (specify):
text
C0514044 (UMLS CUI-1)
C0805443 (UMLS CUI-2)
C0805443 (UMLS CUI-2)
DEATH
Item
Death:
boolean
C0011065 (UMLS CUI-1)
Date
Item
Lost to Follow-up (Date of last contact):
date
C0011008 (UMLS CUI-1)
COMPLIANCE
Item
Poor/ Non- compliance (specify):
text
C1321605 (UMLS CUI-1)
PREGNANCY
Item
Pregnancy:
boolean
C0549206 (UMLS CUI-1)
STUDY CRITERIA
Item
Subject no longer meets study criteria (specify):
text
ADMINISTRATIVE REASON BY SPONSOR
Item
Administrative reason by sponsor:
boolean
Others
Item
Others (Specify):
text